Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice

Vaccine

Volumn 30, Issue 20, 2012, Pages 3126-3135

  Dendouga, Najoua ^a   Fochesato, Michel ^a   Lockman, Laurence ^a   Mossman, Sally ^a   Giannini, Sandra L ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant System; Glycoprotein E; Herpes zoster vaccine; Varicella zoster virus

Indexed keywords

3 O DESACYL 4' MONOPHOSPHORYL LIPID A; ALUMINUM SALT; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN E; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 2; QS 21; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHICKENPOX; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HERPES ZOSTER; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; HERPES ZOSTER VACCINE; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; SAPONINS; TOLL-LIKE RECEPTORS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 84859427365     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.088     Document Type: Article

References (72)

1. Tseng H.F., Smith N., Harpaz R., Bialek S.R., Sy L.S., Jacobsen S.J. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011, 305(2):160-166.
2. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(22):2271-2284.
3. Hope-Simpson R.E. The nature of Herpes Zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-20.
4. Gershon A.A., Gershon M.D., Breuer J., Levin M.J., Oaklander A.L., Griffiths P.D. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010, 48(Suppl. 1):S2-S7.
5. + T cells on reexposure to varicella-zoster virus. J Infect Dis 2004, 190(1):72-82.
6. + T cells after primary infection. J Virol 2006, 80(19):9772-9778.
7. Asanuma H., Sharp M., Maecker H.T., Maino V.C., Arvin A.M. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis 2000, 181(3):859-866.
8. Weinberg A., Levin M.J.V.Z.V. T cell-mediated immunity. Curr Top Microbiol Immunol 2010, 342:341-357.
9. Arvin A.M. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis 2008, 197(Suppl 2):S58-S60.
10. Shaw A.C., Panda A., Joshi S.R., Qian F., Allore H.G., Montgomery R.R. Dysregulation of human Toll-like receptor function in aging. Ageing Res Rev 2011, 10(3):346-353.
11. Shaw A.C., Joshi S., Greenwood H., Panda A., Lord J.M. Aging of the innate immune system. Curr Opin Immunol 2010, 22(4):507-513.
12. Linton P.J., Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004, 5(2):133-139.
13. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005, 352(22):2266-2267.
14. Levin M.J., Oxman M.N., Zhang J.H., Johnson G.R., Stanley H., Hayward A.R., et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008, 197(6):825-835.
15. Hata A., Asanuma H., Rinki M., Sharp M., Wong R.M., Blume K., et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002, 347(1):26-34.
16. Oxman M.N. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010, 51(2):197-213.
17. Weinberg A., Zhang J.H., Oxman M.N., Johnson G.R., Hayward A.R., Caulfield M.J., et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009, 200(7):1068-1077.
18. Garçon N., Chomez P., van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(5):723-739.
19. Garçon N., van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems. Expert Rev Vaccines 2011, 10(4):471-486.
20. Berarducci B., Rajamani J., Reichelt M., Sommer M., Zerboni L., Arvin A.M. Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry. J Virol 2009, 83(1):228-240.
21. Cohen J.I., Straus S.E., Arvin A.M. Varicella-zoster virus replication, pathogenesis and management. Fields Virology 2007, 2773-2818. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, Pennsylvania. D.M. Knipe, P.M. Howley (Eds.).
22. Grose C. The predominant varicella-zoster virus gE and gI glycoprotein complex. Structure-function relationships of human pathogenic viruses 2002, 195-223. Kluwer Academic Publishers, New York, NY. A. Holzenburg, E. Bogner (Eds.).
23. Mo C., Lee J., Sommer M., Grose C., Arvin A.M. The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology 2002, 304(2):176-186.
24. Mallory S., Sommer M., Arvin A.M. Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking. J Virol 1997, 71(11):8279-8288.
25. Berarducci B., Ikoma M., Stamatis S., Sommer M., Grose C., Arvin A.M. Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection. J Virol 2006, 80(19):9481-9496.
26. Berarducci B., Rajamani J., Zerboni L., Che X., Sommer M., Arvin A.M. Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection. Proc Natl Acad Sci USA 2010, 107(1):282-287.
27. Nikkels A.F., Delvenne P., Debrus S., Sadzot-Delvaux C., Piette J., Rentier B., et al. Distribution of varicella-zoster virus gpI and gpII and corresponding genome sequences in the skin. J Med Virol 1995, 46(2):91-96.
28. Bergen R.E., Sharp M., Sanchez A., Judd A.K., Arvin A.M. Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus. Viral Immunol 1991, 4(3):151-166.
29. Fowler W.J., Garcia-Valcarcel M., Hill-Perkins M.S., Murphy G., Harper D.R., Jeffries D.J., et al. Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus. Virology 1995, 214(2):531-540.
30. + T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol 2008, 152(3):522-531.
31. Wu L., Forghani B. Characterization of neutralizing domains on varicella-zoster virus glycoprotein E defined by monoclonal antibodies. Arch Virol 1997, 142(2):349-362.
32. + phenotype. J Immunol 1991, 146(1):257-264.
33. Bergen R.E., Diaz P.S., Arvin A.M. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J Infect Dis 1990, 162(5):1049-1054.
34. Ceroni A., Sibani S., Baiker A., Pothineni V.R., Bailer S.M., LaBaer J., et al. Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray. Mol Biosyst 2010, 6(9):1604-1610.
35. Sharp M., Terada K., Wilson A., Nader S., Kinchington P.E., Ruyechan W.T., et al. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis 1992, 165(5):852-858.
36. Haumont M., Jurdan M., Kangro H., Jacquet A., Massaer M., Deleersnyder V., et al. Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization. J Med Virol 1997, 53(1):63-68.
37. Vafai A. Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine. Vaccine 1995, 13(14):1336-1338.
38. Kimura H., Wang Y., Pesnicak L., Cohen J.I., Hooks J.J., Straus S.E., et al. Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis. J Infect Dis 1998, 178(2):310-317.
39. Ludvíková V., Kunke D., Hamšiková E., Kutinová L., Vonka V. Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant. J Gen Virol 1991, 72(Pt 6):1445-1449.
40. Jacquet A., Haumont M., Massaer M., Garcia L., Mazzu P., Daminet V., et al. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Vaccine 2002, 20(11-12):1593-1602.
41. Hasan U.A., Harper D.R., Argent S., Layton G., Wren B.W., Morrow W.J. Immunization with a DNA expression vector encoding the varicella zoster virus glycoprotein E (gE) gene via intramuscular and subcutaneous routes. Vaccine 2000, 18(15):1506-1514.
42. Haumont M., Jacquet A., Massaer M., Deleersnyder V., Mazzu P., Bollen A., et al. Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells. Virus Res 1996, 40(2):199-204.
43. Lowry P.W., Solem S., Watson B.N., Koropchak C.M., Thackray H.M., Kinchington P.R., et al. Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62. J Gen Virol 1992, 73(Pt 4):811-819.
44. Vafai A. Antigenicity of a candidate varicella-zoster virus glycoprotein subunit vaccine. Vaccine 1993, 11(9):937-940.
45. Mahalingam R., Messaoudi I., Gilden D. Simian varicella virus pathogenesis. Curr Top Microbiol Immunol 2010, 342:309-321.
46. Schmid D.S., Jumaan A.O. Impact of varicella vaccine on varicella-zoster virus dynamics. Clin Microbiol Rev 2010, 23(1):202-217.
47. Mettens P., Dubois P.M., Demoitié M.A., Bayat B., Donner M.N., Bourguignon P., et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 2008, 26(8):1072-1082.
48. E in 5 to 17 month old Kenyan and Tanzanian Children. PLoS One 2010, 5(11):e14090.
49. Maecker H.T., Maino V.C., Picker L.J. Immunofluorescence analysis of T-cell responses in health and disease. J Clin Immunol 2000, 20(6):391-399.
50. Maecker H.T., Dunn H.S., Suni M.A., Khatamzas E., Pitcher C.J., Bunde T., et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001, 255(1-2):27-40.
51. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453(7198):1122-1126.
52. Kool M., Pétrilli V., De Smedt T., Rolaz A., Hammad H., van Nimwegen M., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181(6):3755-3759.
53. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21(1):23-29.
54. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based Adjuvant System, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183(10):6186-6197.
55. Casella C.R., Mitchell T.C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008, 65(20):3231-3240.
56. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005, 11(4 Suppl.):S63-S68.
57. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5(7):505-517.
58. Centers for Disease Control and Prevention Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2008, 57:1-30.
59. Zak-Prelich M., McKenzie R.C., Sysa-Jedrzejowska A., Norval M. Local immune responses and systemic cytokine responses in zoster: relationship to the development of postherpetic neuralgia. Clin Exp Immunol 2003, 131(2):318-323.
60. Zhang Y., Cosyns M., Levin M.J., Hayward A.R. Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures. Clin Exp Immunol 1994, 98(1):128-133.
61. Arvin A., Abendroth A. VZV: immunobiology and host response. Human herpesviruses: biology, therapy, and immunoprophylaxis 2007, Cambridge University Press, Cambridge. A. Arvin, G. Campadelli-Fiume, E. Mocarski, P.S. Moore, B. Roizman, R. Whitley (Eds.).
62. + T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis 2003, 188(1):40-52.
63. + T cells specific for immediate-early 63 protein of varicella-zoster virus. Eur J Immunol 2007, 37(12):3393-3403.
64. + T cells many decades after primary infection. J Infect Dis 2007, 195(5):660-664.
65. Arnold C.R., Wolf J., Brunner S., Herndler-Brandstetter D., Grubeck-Loebenstein B. Gain and loss of T cell subsets in old age-age-related reshaping of the T cell repertoire. J Clin Immunol 2011, 31(2):137-146.
66. Chen W.H., Kozlovsky B.F., Effros R.B., Grubeck-Loebenstein B., Edelman R., Sztein M.B. Vaccination in the elderly: an immunological perspective. Trends Immunol 2009, 30(7):351-359.
67. Weinberger B., Herndler-Brandstetter D., Schwanninger A., Weiskopf D., Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008, 46(7):1078-1084.
68. Kumar R., Burns E.A. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines 2008, 7(4):467-479.
69. Kovaiou R.D., Herndler-Brandstetter D., Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med 2007, 9(3):1-17.
70. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(25):2414-2423.
71. Langley J.M., Sales V., McGeer A., Guasparini R., Predy G., Meekison W., et al. A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥65 years of age. Vaccine 2009, 27(42):5913-5919.
72. Wroblewska Z., Valyi-Nagy T., Otte J., Dillner A., Jackson A., Sole D.P., et al. A mouse model for varicella-zoster virus latency. Microb Pathog 1993, 15(2):141-151.